Vir Biotechnology (VIR) Non-Current Deffered Revenue (2018 - 2025)

Vir Biotechnology has disclosed Non-Current Deffered Revenue across 8 years of filings, most recently posting $9.4 million for Q3 2025.

• Non-Current Deffered Revenue for Q3 2025 came in at $9.4 million, changed N/A year-over-year; the trailing twelve-month figure through Sep 2025 was $9.4 million (changed N/A YoY), and the FY2023 annual result was $1.5 million, down 97.13% from the prior year.
• Non-Current Deffered Revenue came in at $9.4 million for Q3 2025 at Vir Biotechnology, up from $1.5 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $55.5 million in Q2 2021 to a low of $1.5 million in Q4 2023.
• The 5-year median for Non-Current Deffered Revenue is $7.6 million (2022), against an average of $25.5 million.
• Across the five-year window, Non-Current Deffered Revenue surged 1354.68% in 2021 and slumped 97.13% in 2023, its largest moves.
• Vir Biotechnology's Non-Current Deffered Revenue stood at $3.8 million in 2021, then jumped by 1294.68% to $53.2 million in 2022, then plunged by 97.13% to $1.5 million in 2023, then changed by 0.0% to $1.5 million in 2024, then jumped by 518.15% to $9.4 million in 2025.
• The last three Non-Current Deffered Revenue figures came in at $9.4 million (Q3 2025), $1.5 million (Q1 2024), and $1.5 million (Q4 2023), per Business Quant data.